



Melanoma: Clinical Trials and Translational Research

Guest Editors:

Dr. Roberta Giuffrida

Dr. Claudio Guarneri

Prof. Dr. Linda Tognetti

Dr. Claudio Conforti

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

Melanoma is the deadliest type of skin cancer. It arises from melanocytes in skin, mucous membranes, eyes, or the central nervous system, **following genetic, epigenetic and allogenic alterations**, and has the potential to spread to any organ of the body. Generally, this tumor can be cured, if diagnosed in the early stages, with high survival rates. However, patients with advanced disease have a poor prognosis.

In the past two decades, much progress has been made in the diagnosis and treatment of melanoma, also thanks to the increased knowledge of tumor biology, which has led to a targeted approach and personalized melanoma therapeutic strategies.

The aim of this Special Issue is to publish innovative and high quality original/review articles focused on the development and improvement of new ways to prevent, diagnose, and treat melanoma by translating findings observed in a laboratory into clinical applications.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)